Rezolute’s stock up on interim Phase III tumour HI data

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint

Sector Update: Healthcare Stocks Softer Late Afternoon

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment

Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’